Medical emergency?Emergency? Call 911. Nearest emergency roomsNearest ERs

Prescription medicine

Aprocitentan

Drug class: Endothelin Receptor Antagonist

The FDA’s “Established Pharmacologic Class”: the group of medicines that work in a similar way.

Official FDA data, not advice

Everything here comes from the U.S. Food and Drug Administration (FDA): the drug label, the NDC Directory, Drugs@FDA, recall reports and the drug shortage list. Each fact shows its source and date.

This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.

In an emergency, call 911. If someone may have taken too much of a medicine, call Poison Help: 1‑800‑222‑1222.

Quick answers

What is Aprocitentan used for?
The FDA-approved label (Tryvio, Idorsia Pharmaceuticals Ltd, August 14, 2026) says: “TRYVIO, in combination with other antihypertensive drugs, is indicated for the treatment of hypertension, to lower blood pressure (BP) in adult patients who are not adequately controlled on other drugs. Lowering BP reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. …” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Does Aprocitentan have a boxed warning?
Yes. The FDA label for Tryvio has a boxed warning, the FDA’s strongest warning. Read it on the full label and ask your pharmacist.
Is there a shortage of Aprocitentan?
No current shortage is listed by the FDA for the products of this medicine (FDA data from October 30, 2026).
Has Aprocitentan been recalled?
No recall linked to the products of this medicine appears in the FDA enforcement reports we use.
Who makes Aprocitentan?
1 company lists prescription products of Aprocitentan in the FDA NDC Directory, including Idorsia Pharmaceuticals Ltd.

What Aprocitentan is used for

Quoted from the “Indications and Usage” section of the FDA-approved label.

TRYVIO, in combination with other antihypertensive drugs, is indicated for the treatment of hypertension, to lower blood pressure (BP) in adult patients who are not adequately controlled on other drugs. Lowering BP reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. …

— FDA label: Tryvio, Idorsia Pharmaceuticals Ltd, effective August 14, 2026. Read the full label on DailyMed →

This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.

Conditions named on the label

These condition names appear word for word in the label’s “Indications and Usage” text (matched with a reviewed table). Each page lists hospitals whose own websites name the condition.

Related medical specialties

Boxed warning

A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.

This label has a boxed warning. Read it on the full label →

Forms and how it is given

Dosage formsTablet, film coated
RouteOral
Prescription products1 in the FDA NDC Directory
Brand namesTryvio

Companies that list this medicine

Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.

FDA approval history

  • NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
Brand and biologic applications
ApplicationSponsorApprovedLater changes approved
NDA217686
TRYVIO
IdorsiaMarch 19, 2024 4, latest August 6, 2026
2026: Labeling · 2025: REMS · 2024: REMS

Shortage status

The FDA drug shortage list does not show these products.

FDA Drug Shortages database →

Recalls

No recall linked to these products (by their NDC code) appears in the FDA enforcement reports.

Official identifiers

RxCUI (RxNorm)2679064, 2679070
SPL set ID of the quoted labeldfe7a2ee-612c-4aba-834a-d68e6b59a0a6
FDA labels (SPL)1
FDA applicationsNDA217686
Active ingredients (FDA)APROCITENTAN

Sources

  1. FDA-approved label on DailyMed (National Library of Medicine) — Tryvio, Idorsia Pharmaceuticals Ltd, effective August 14, 2026; via openFDA, FDA data exported October 30, 2026, retrieved October 31, 2026
  2. NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
  3. Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
  4. Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
  5. Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026

openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →

Report an error → · Information for medicine makers